Close Menu

miRNA

IP Update: Aug 27, 2009

Premium

USPTO Publishes Three Patents, Ten Patent Applications Related to RNAi

American and Serbian researchers have identified telltale miRNA changes in the saliva of individuals with oral cancer — a finding that they say may eventually yield saliva-based oral cancer diagnostic tests.

The arrangement gives Super Religare the rights to distribute the tests in India, Saudi Arabia, Qatar, and the United Arab Emirates.

SRL will distribute Rosetta’ Genomics’ microRNA cancer tests in India, Saudi Arabia, Qatar, and in the UAE.

Warnex will market the tests and send tissue samples from its customers to Rosetta's Philadelphia-based lab for analysis.

The application, No. 20060058266, is entitled "Chemically modified oligonucleotides," and claims "composition and methods for making and using chemically modified oligonucleotide agents for inhibiting gene expression," according to its abstract.

Marketing director Dalsoo Kim said the company now sells a PANArray miRNA expression-profiling kit for surveying stem cell-related miRNAs. The launch follows its debut in June of a kit for profiling cancer-related miRNAs.

Warnex Medical Laboratories and Rosetta Genomics have reached an exclusive distribution agreement that applies to three miRview tests in Canada.

Papers of Note: Aug 6, 2009

Premium

RNAi-Related Papers Published July 2009

In the advance online version of Nucleic Acids Research, Santaris investigators reported data identifying miR-155, an miRNA involved in immune-system regulation, as a possible therapeutic target for chronic inflammatory diseases such as rheumatoid arthritis.

Pages

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.